Advertisement Β· 728 Γ— 90
#
Hashtag
#RLMD
Advertisement Β· 728 Γ— 90
🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from πŸ”₯ INSIDERFINANCE.COM πŸ”₯
#CHYM, #FFWM, #RLMD, #COGT, #MSI

#OptionFlow #OptionsTrading #Trading

0 0 0 0
Preview
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update Relmada Therapeutics (Nasdaq: RLMD) reported strong Phase 2 NDV-01 data and completed a $160 million PIPE financing to fund development through 2029. Key clinical results showed a 95% CR rate at any time and a 76% durable CR at 12 months in high‑risk NMIBC.The company is aligned with the FDA on two registrational pathways and plans to initiate the Phase 3 RESCUE program in mid‑2026, with IND clearance targeted the same period.

#RLMD Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing Relmada Therapeutics (Nasdaq: RLMD) announced an oversubscribed private placement expected to raise approximately $160.0 million gross, before placement agent fees and offering expenses. The financing consists of 29,474,569 common shares at $4.75 and 4,210,527 pre-funded warrants at $4.749.The pre-funded warrants carry a $0.001 exercise price. Closing is expected on or about March 11, 2026, subject to customary conditions. Proceeds will be used for working capital and advancing R&D. The company agreed to file resale registration rights.

#RLMD Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer Relmada Therapeutics (Nasdaq: RLMD) reported 12-month Phase 2 interim data for NDV-01 in high-risk non-muscle invasive bladder cancer. The study showed a 12-month complete response (CR) rate of 76% overall and 80% in BCG-unresponsive patients, with 95% and 94% CR rates at any time, respectively. No patients progressed to muscle-invasive disease or required radical cystectomy. No β‰₯ Grade 3 treatment-related adverse events or treatment discontinuations were reported. Relmada plans IND clearance and initiation of the Phase 3 RESCUE program in mid-2026, with initial Phase 3 3-month readouts expected by year-end 2026.

#RLMD Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications Relmada Therapeutics (Nasdaq: RLMD) announced FDA written feedback supporting its registrational development pathway for NDV-01 in two separate non-muscle invasive bladder cancer (NMIBC) indications.The FDA indicated a single-arm, open-label registrational trial is appropriate for 2nd-line refractory, high-grade BCG-unresponsive NMIBC with carcinoma in situ (CIS). The agency also provided supportive written feedback for a single randomized-to-observation registrational trial in intermediate-risk NMIBC in the adjuvant setting. Relmada expects to initiate both Phase 3 registrational trials in 1H 2026.

#RLMD Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

JUST IN: ( NASDAQ: #RLMD ) Relmada Therapeutics Inc. (NASDAQ: RLMD) is a Stock Spotlight on 12/30

0 0 0 0

NEWS: ( NASDAQ: #RLMD ) Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

0 0 0 0
Preview
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in

#RLMD Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

JUST IN: ( NASDAQ: #RLMD ) Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

0 0 0 0
Preview
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Relmada Therapeutics (Nasdaq: RLMD) reported Q3 2025 results and pipeline updates on Nov 13, 2025, highlighting a 92% complete response rate (anytime) at 9-month follow-up for NDV-01 in NMIBC and favorable safety.The company secured FDA alignment on Phase 3 pathways with two potential registrational routes (high-risk 2nd-line BCG-unresponsive single-arm and intermediate-risk adjuvant randomized trial) and expects to initiate studies in H1 2026. Relmada closed an underwritten offering on Nov 5, 2025 providing approximately $100M gross proceeds and said available cash including offering proceeds should support operations into 2028.

#RLMD Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

BREAKING NEWS: ( NASDAQ: #RLMD ) RLMD - Historical Price Movements Surrounding Earnings

0 0 0 0

Just In: ( NASDAQ: #RLMD ) RLMD - Historical Earnings Price Analysis

0 0 0 0
Preview
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Relmada Therapeutics (NASDAQ: RLMD) priced an underwritten offering to raise approximately $100 million in gross proceeds by selling 40,142,000 common shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 5,315,000 common shares.Common shares priced at $2.20 each; pre-funded warrants priced at $2.199 each (reflecting a $0.001 exercise price). The offering is expected to close on November 5, 2025, subject to customary closing conditions. Institutional investors participated and Jefferies, Leerink Partners and Mizuho acted as book-runners. Net proceeds will fund working capital, clinical studies, systems and potential strategic investments.

#RLMD Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Issues Mid-Year CEO Letter to Shareholders Relmada Therapeutics (NASDAQ: RLMD) has issued a mid-year CEO letter highlighting significant developments in 2025. The company has expanded its portfolio with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and Sepranolone for compulsivity disorders.NDV-01 demonstrated impressive 91% complete response rate in Phase 2 six-month follow-up data. The company plans to initiate Phase 3 trials in H1 2026. To strengthen the program, Relmada appointed Dr. Raj S. Pruthi as CMO-Oncology and Dr. Yair Lotan as Clinical Advisory Board Chair.For Sepranolone, following positive proof-of-concept data in Tourette's syndrome, Relmada plans to begin Phase 2 trials for Prader-Willi Syndrome in H1 2026, targeting a population of 350,000-400,000 patients worldwide.

#RLMD Relmada Issues Mid-Year CEO Letter to Shareholders

www.stocktitan.net/news/RLMD/relmada-issues...

0 0 0 0

NEWS: ( NASDAQ: #RLMD ) Morning Market Briefing: Micro-Caps Primed for Breakouts

0 0 0 0
Leading Indicators, Thursday August 21, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Thu Aug 21st - #USIO #TSP #RLMD #NEOV #MOVE #LIMN #INVE #GREE #EM #CRGX #ACNT #VET #TLYS #DHX #CLB #ASIX - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC Relmada Therapeutics (NASDAQ:RLMD) reported significant progress in its Q2 2025 financial results and clinical developments. The company announced impressive 6-month follow-up data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 91% overall response rate with favorable safety profiles. No patients progressed to muscle invasive disease or required radical cystectomy.Financial results showed reduced losses, with Q2 2025 net loss at $9.9 million ($0.30 per share) compared to $17.8 million in Q2 2024. The company maintained $20.6 million in cash and equivalents as of June 30, 2025. Relmada plans to initiate a Phase 3 registration trial for NDV-01 in 1H 2026 and advance sepranolone into Phase 2 studies for Prader-Willi syndrome.

#RLMD Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Relmada Therapeutics (RLMD) reported Q1 2025 financial results and provided pipeline updates. The company highlighted positive Phase 2 proof-of-concept data for NDV-01, showing a 90% overall response rate in non-muscle invasive bladder cancer patients. Key financial metrics include: net loss of $17.5 million ($0.58/share), R&D expenses of $11.9 million, and cash position of $27.1 million. NDV-01, a sustained-release intravesical formulation, demonstrated 89% high-grade recurrence-free survival in papillary disease and 100% complete response in carcinoma in situ. The company plans to initiate a Phase 3 trial for NDV-01 and a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026.

#RLMD Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial New Phase 2 data reveals NDV-01's strong efficacy in bladder cancer treatment, with 90% disease-free status and favorable safety profile. See full results.

#RLMD Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0
Preview
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 Net loss improves to $18.6M as Relmada advances NDV-01 and sepranolone programs. Phase 2 data expected in 2025, with pivotal trials planned. See development timeline.

#RLMD Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours Exclusive license for innovative bladder cancer therapy targeting 600k+ patients. Superior 10-day sustained release could transform treatment. Full analysis inside.

#RLMD Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Groundbreaking Tourette Treatment Shows 69% QoL Improvement in Clinical Trial - Relmada's Latest Acquisition Relmada acquires Sepranolone, showing 28% tic reduction and major QoL improvements in Phase 2a Tourette syndrome trial. Zero CNS side effects reported. Phase 2b ready.

#RLMD Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Preview
Relmada Therapeutics Halts Major Phase 3 Trials, Explores Strategic Sale Options Relmada discontinues key REL-1017 Phase 3 studies following monitoring committee review, initiates strategic alternatives exploration including potential company sale.

#RLMD Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

#StockMarket #stocks #news

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

#RLMD Relmada Therapeutics to Present at Jefferies London Healthcare Conference

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0

#RLMD Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

www.stocktitan.net/news/RLMD/relmada-therap...

0 0 0 0
Post image

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from πŸ”₯ INSIDERFINANCE.COM πŸ”₯
#SLQT, #SYY, #RLMD, #INSG, #VRNA

#OptionFlow #OptionsTrading #Trading

0 0 0 0
Preview
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL Getting your Trinity Audio player ready... Investors seeking promising opportunities in the biotech and tech sectors should keep an eye on several companies showing potential for significant market tu...

(9) SmallCap Biotech & Tech Companies To Watch
thestreetreports.com/10-smallcap-...
#PRSO #ZVSA #DYAI #RLMD #VTAK #INBS #KAVL

0 0 0 0